Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
George J Brewer. (2009) The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opinion on Investigational Drugs 18:1, pages 89-97.
Read now
Read now
Articles from other publishers (30)
Osman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, Sonia Vallet & Klaus Podar. (2023) Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications. Cytokine 161, pages 156062.
Crossref
Crossref
James R. Berenson, Clara Kim, Sean Bujarski, Jennifer To, Tanya M. Spektor, Daisy Martinez, Carley Turner, Matthew Ghermezi, Benjamin M. Eades, Regina A. Swift, Gary Schwartz, Shahrooz Eshaghian, Robert A. Moss, Stephen Lim & Robert Vescio. (2022) A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematological Oncology 40:5, pages 906-913.
Crossref
Crossref
Vijay Sagar Madamsetty, Reza Mohammadinejad, Ilona Uzieliene, Noushin Nabavi, Ali Dehshahri, Jomarien García-Couce, Shima Tavakol, Saeid Moghassemi, Arezoo Dadashzadeh, Pooyan Makvandi, Abbas Pardakhty, Abbas Aghaei Afshar & Ali Seyfoddin. (2022) Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. ACS Biomaterials Science & Engineering 8:5, pages 1763-1790.
Crossref
Crossref
Elaheh Asgari Dafe, Nastaran Rahimi, Nina Javadian, Pegah Dejban, Monika Komeili, Sepideh Modabberi, Mehdi Ghasemi & Ahmad Reza Dehpour. (2021) Effect of Lenalidomide on Pentylenetetrazole-Induced Clonic Seizure Threshold in Mice: A Role for N-Methyl-D-Aspartic Acid Receptor/Nitric Oxide Pathway. Journal of Epilepsy Research 11:1, pages 6-13.
Crossref
Crossref
Rongrong Li, Bo Zhao, Xianlang Chen, Jieyu Zhang, Zhiying Liu, Xianling Zhu & Deman Han. (2021) Solubility and apparent thermodynamic analysis of pomalidomide in (acetone + ethanol/isopropanol) and (ethyl acetate + ethanol/isopropanol) and its correlation with thermodynamic model. The Journal of Chemical Thermodynamics 154, pages 106345.
Crossref
Crossref
James R. Berenson, Jennifer To, Tanya M. Spektor, Daisy Martinez, Carley Turner, Armando Sanchez, Matthew Ghermezi, Benjamin M. Eades, Regina A. Swift, Gary Schwartz, Shahrooz Eshaghian, Laura Stampleman, Robert A. Moss, Stephen Lim & Robert Vescio. (2020) A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research 26:10, pages 2346-2353.
Crossref
Crossref
Rajeev Ramakrishna, Terrence H. Diamond, William Alexander, Arumugam Manoharan & Terry Golombick. (2020) Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy. Clinical Case Reports 8:4, pages 739-744.
Crossref
Crossref
Süreyya Ölgen. 2020. Drug Repurposing in Cancer Therapy. Drug Repurposing in Cancer Therapy
395
437
.
Javad Sharifi-Rad, Adem Ozleyen, Tugba Boyunegmez Tumer, Charles Oluwaseun Adetunji, Nasreddine El Omari, Abdelaali Balahbib, Yasaman Taheri, Abdelhakim Bouyahya, Miquel Martorell, Natália Martins & William C. Cho. (2019) Natural Products and Synthetic Analogs as a Source of Antitumor Drugs. Biomolecules 9:11, pages 679.
Crossref
Crossref
Sureyya Olgen & Lakshmi P. Kotra. (2019) Drug Repurposing in the Development of Anticancer Agents. Current Medicinal Chemistry 26:28, pages 5410-5427.
Crossref
Crossref
Dávid Vrábel, Luděk Pour & Sabina Ševčíková. (2019) The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Reviews 34, pages 56-66.
Crossref
Crossref
Clark W. Distelhorst. (2018) Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1865:11, pages 1795-1804.
Crossref
Crossref
Krzysztof Z Łączkowski & Angelika Baranowska-Łączkowska. (2018) Recent studies on the thalidomide and its derivatives. Future Medicinal Chemistry 10:18, pages 2133-2136.
Crossref
Crossref
Sahdeo Prasad, Subash C. Gupta & Bharat B. Aggarwal. (2016) Serendipity in Cancer Drug Discovery: Rational or Coincidence?. Trends in Pharmacological Sciences 37:6, pages 435-450.
Crossref
Crossref
Shaunna L. Beedie, Holly M. Rore, Shelby Barnett, Cindy H. Chau, Weiming Luo, Nigel H. Greig, William D. Figg & Neil Vargesson. (2016)
In vivo
screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
. Oncotarget 7:22, pages 33237-33245.
Crossref
Crossref
María J Cejalvo & Javier de la Rubia. (2015) Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Future Oncology 11:11, pages 1643-1658.
Crossref
Crossref
Meletios A. Dimopoulos, Paul G. Richardson, Philippe Moreau & Kenneth C. Anderson. (2014) Current treatment landscape for relapsed and/or refractory multiple myeloma. Nature Reviews Clinical Oncology 12:1, pages 42-54.
Crossref
Crossref
Nasr Y Khalil, Ibrahim A Darwish, Tanveer A Wani & Abdel-Rahman A Al-Majed. (2013) Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. Chemistry Central Journal 7:1.
Crossref
Crossref
Gordon F. Rushworth, Stephen J. Leslie, Peter Forsyth & Claire Vincent. (2012) Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma. Therapeutic Advances in Drug Safety 3:3, pages 115-122.
Crossref
Crossref
Kun Jiang, Kunjie Li, Feng Qin, Xiumei Lu & Famei Li. (2011) Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities. Toxicology in Vitro 25:5, pages 1033-1038.
Crossref
Crossref
Güllü GörgünElisabetta CalabreseEnder SoydanTeru HideshimaGiulia PerroneMadhavi BandiDiana CirsteaLoredana SantoYiguo HuYu-Tzu TaiSabikun NaharNaoya MimuraClaire FabreNoopur Raje, Nikhil Munshi, Paul RichardsonKenneth C. Anderson. (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:17, pages 3227-3237.
Crossref
Crossref
Dan Jia, Nathan A. Koonce, Roopa Halakatti, Xin Li, Shmuel Yaccoby, Frances L. Swain, Larry J. Suva, Leah Hennings, Marc S. Berridge, Scott M. Apana, Kevin Mayo, Peter M. Corry & Robert J. Griffin. (2010) Repression of Multiple Myeloma Growth and Preservation of Bone with Combined Radiotherapy and Anti-angiogenic Agent. Radiation Research 173:6, pages 809-817.
Crossref
Crossref
Thomas Reske, Mariateresa Fulciniti & Nikhil C. Munshi. (2010) Mechanism of action of immunomodulatory agents in multiple myeloma. Medical Oncology 27:S1, pages 7-13.
Crossref
Crossref
Jacob P. Laubach, Paul G. Richardson & Kenneth C. Anderson. (2010) The evolution and impact of therapy in multiple myeloma. Medical Oncology 27:S1, pages 1-6.
Crossref
Crossref
Monica De Matteo, Anna Elisabetta Brunetti, Eugenio Maiorano, Paola Cafforio, Franco Dammacco & Franco Silvestris. (2010) Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. Leukemia Research 34:2, pages 243-249.
Crossref
Crossref
Zhi-Yi Zhang, Mei Chen, Jennifer Chen, Mahesh V. Padval & Vikram V. Kansra. (2009) Biotransformation and in vitro assessment of metabolism-associated drug–drug interaction for CRx-102, a novel combination drug candidate. Journal of Pharmaceutical and Biomedical Analysis 50:2, pages 200-209.
Crossref
Crossref
Pei Lin. (2009) Plasma Cell Myeloma. Hematology/Oncology Clinics of North America 23:4, pages 709-727.
Crossref
Crossref
Peter H. Wiernik. (2008) Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Current Treatment Options in Oncology 10:1-2, pages 1-15.
Crossref
Crossref
Pei Lin. (2009) Plasma cell neoplasms. Diagnostic Histopathology 15:3, pages 134-141.
Crossref
Crossref
Christine VolkUlrike Klein. (2009) Management of Multiple Myeloma and Myelodysplastic Syndrome: Focus on Lenalidomide. Clinical Medicine. Therapeutics 1, pages CMT.S2295.
Crossref
Crossref